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Since 1999 we have been studying and treating patients 
with suspected inherited and/or acquired thrombophilia. 
Some of them have been referred to us by other specialists, 
mainly ophthalmologists and neurologists, but interestingly, 
most of them have come to our clinic referred to by friends 
or relatives, this being most likely, to our regret, a relec-
tion of the importance that other specialists place on this 
condition.
Diagnosis
Inherited thrombophilia is a rather common condition which 
explains several cases of thrombosis. An inherited thrombo-
philic condition should be suspected in cases of: Thrombosis 
in individuals of less than 45 years, thrombosis in unusual 
sites, thrombosis without other triggering conditions, resis-
tance to antithrombotic treatments, recurrent miscarriages 
and a family history of thrombosis. Most cases of thrombosis 
in these persons present themselves when exposed to other 
acquired thrombophilic conditions, the most frequent ones 
being estrogen treatment, puerperium and prolonged im-
mobilization.
In the vast majority of cases, patients coming to our clinic 
have been studied incompletely by other physicians and gi-
ven empirically antiplatelet drugs, anticoagulants or both. 
Many of these patients have been frightened by their physi-
cians about having a potentially mortal disease at a young 
age.
a) Thrombophilic screening
Stemming from our studies of more than 15 years, we have 
designed 2 thrombophilic screening sets of studies in Mexi-
can patients being studied for thrombophilia. Table 1 shows 
the salient inherited thrombophilic conditions which we 
have identiied in Mexicans and which were used to design 
these 2 thrombophilic proiles:
1. Full thrombophilic screening proile: MTHFR C677T 
gene mutation, investigation of the sticky platelet 
syndrome, activated protein C resistance aPCR 
phenotype, factor V leiden mutation, HR2 haploty-
pe of the factor V gene, anti-phospholipid antibo-
dies, factor II G20210A gene mutation, protein C 
levels, protein S levels, antithrombin III levels, PnH 
phenotype in red and white blood cells, JAK-2 
V617F gene mutation, and lupus anticoagulant
2. Limited thrombophilic screening proile: MTHFR 
C677T gene mutation, investigation of the sticky 
platelet syndrome, aPCR phenotype, and anti-
phospholipid antibodies.
We encourage all patients to have the full laboratory 
workup done, since the chances of identifying the thrombo-
philic conditions are above 90%, provided all the workup is 
done. We reserve the limited proile for patients who are 
unable to defray the cost of the full workup. Before ma- 
king the set of studies, we instruct the patients to stop both 
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antiplatelet drugs and/or anticoagulants, and to switch into 
low molecular weight heparin 5-7 days before drawing the 
blood samples. Most of the times we identify 2 or more in-
herited thrombophilic conditions which coexist with another 
acquired thrombophilic state in order to develop a full 
blown thrombotic episode.
Treatment
once the diagnosis is done, employing the above mentioned stu-
dies, we make the following recommendations to the patients:
a) Sticky platelet syndrome (SPS)
This inherited condition leads into both arterial and venous 
thrombosis and, until recently, its true importance in medi-
cal literature had been neglected. Patients with the SPS 
rethrombose when given oral anticoagulants; they must be 
treated with antiplatelet drugs. Aspirin (100 mg/day) is ade-
quately tolerated by more than 90% of patients; the rest are 
to be given clopidogrel or other antiplatelet drugs. The test 
to deine SPS must be repeated 4 weeks after starting aspi-
rin; if the aggregation proiles normalize it must be kept 
indeinitely; less than 10% of individuals need other antipla-
telet drugs to reverse the platelet hyperaggregability. SPS 
patients, adequately treated, have a less than 5% chance of 
re-thrombosing.
b) MTHFR C677T gene mutation
This genetic condition probably is not, by itself, enough to 
create thrombophilia, but added to other ones, it may have 
signiicance. On the other hand, the prevalence of this mu-
tation in the normal population in Mexico is extremely high. 
Since this mutation may lead into hyperhomocystinemia 
which may be aggravated by folic acid deiciency, we re-
commend folic acid, 5 mg/day, indeinitely to individuals 
displaying this gene mutation and having suffered a throm-
botic episode.
c) Activated PCR aPCR phenotype
This condition can be either inherited or acquired. In Mexi-
cans mestizos the acquired forms (antiphospholipid antibo-
dies, increased factor VIII levels) are considerably more 
frequent. Patients with inherited forms of aPCR who have 
had a thrombosis probably need an anticoagulant indeini-
tely. We tend to use the new oral anticoagulants (noACs) 
more than vitamin K antagonists and prefer rivaroxaban 
which is used once a day. Individuals with acquired forms of 
aPCR need the anticoagulant at least while the laboratory 
phenomenon is present. 
d) other inherited conditions
Protein S deiciency, protein C deiciency and anti-thrombin 
III deiciency, all of them very infrequent in Mexicans mesti-
zos, probably need lifelong anticoagulation. Again, we tend 
to use the noACs more than vitamin K antagonists and pre-
fer rivaroxaban which is used once a day. NOACs are signii-
cantly more expensive than vitamin K antagonists, but in 
the long turn, needing no laboratory control and being less 
related to severe hemorrhages, may be a good option.
Conclusion
With a full laboratory workup, we are now able to identify 
inherited and acquired thrombophilic conditions in more 
than 90% of individuals having a clinical marker of thrombo-
philia. These studies should ideally be done in persons studied 
and treated by cardiologists, angiologists, gastroenterologists, 
neurologists, gynecologists, ophthalmologists and other spe-
cialists dealing with either arterial or venous thrombosis, in 
order to properly identify the conditions and prevent future 
re-thrombotic episodes. Even hematologists still consider the-
se studies and treatments as experimental or non-evidence-
based. As a result of studying these conditions in more than 
500 Mexicans mestizos, we have been able to deine throm-
bophilic proiles, which could be used to both identify these 
diseases and deine the more adequate treatment.1-16
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